Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acomplia’s Large European Cash Market Not Affecting Dropout Rate – Sanofi

Executive Summary

A substantial portion of European patients purchasing Sanofi-Aventis' Acomplia pay entirely out-of-pocket for the obesity drug

You may also be interested in...



Sanofi-Aventis Zimulti (correction)

Zimulti (rimonabant) is a CB-1 receptor antagonist; a recent article in "The Pink Sheet" mischaracterized the product. Rimonabant is "approvable" at FDA for obesity and "not approvable" for smoking cessation (1"The Pink Sheet" May 7, 2007, p. 25)...

Sanofi-Aventis Zimulti (correction)

Zimulti (rimonabant) is a CB-1 receptor antagonist; a recent article in "The Pink Sheet" mischaracterized the product. Rimonabant is "approvable" at FDA for obesity and "not approvable" for smoking cessation (1"The Pink Sheet" May 7, 2007, p. 25)...

Drug Names Will Be Reviewed By FDA Within 90 Days Under PDUFA Timetable

FDA is establishing timetables for review of proprietary drug names as part of the next cycle of the Prescription Drug User Fee Act

UsernamePublicRestriction

Register

PS048315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel